Alterity Granted U.S. FDA Fast Track Designation for ATH434
Filed with ASX · · 5 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
- Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
- Options Prospectus
- Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
- Alterity Phase 2 Presentation at AAN 2025
Later from Alterity Therapeutics
- Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
- Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
- Alterity Therapeutics Prominently Featured at the International MSA Congress
- Alterity Therapeutics to Provide Corporate Update in Fireside Chat
- Response to ASX Price Query
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics